For people living with long COVID, persistent fatigue can make everyday activities feel overwhelming. A small clinical trial offers an encouraging—but still preliminary—look at whether a cord-blood-derived cell therapy could help.
Published January 9, 2026, in eClinicalMedicine, the study examined REGENECYTE in adults with ongoing post-COVID symptoms. Its findings suggest potential improvements in fatigue and quality of life, while highlighting the need for larger studies before drawing firm conclusions.
What Did the Study Explore?
Researchers enrolled 30 adults, ages 18–65, who had experienced long COVID symptoms for six to 18 months. Twenty participants received REGENECYTE, while ten received a saline placebo. Each participant received three intravenous infusions spaced three weeks apart, with follow-up continuing through week 26.
REGENECYTE is a donor cord-blood-derived product containing blood-forming progenitor cells and immune cells. It is not the same as the mesenchymal stem-cell treatments often discussed in regenerative medicine marketing. That distinction matters: findings about one cell product cannot automatically establish benefits for another.
What Were the Results?
The most notable finding involved fatigue. On the study’s 0–11 fatigue scale, average scores dropped from approximately 6.8 to 1.0 in the treatment group. In comparison, the placebo group’s scores declined from approximately 7.7 to 5.2 by week 26. Physical fatigue showed the greatest improvement.
Participants receiving REGENECYTE also reported improvements in overall health and quality-of-life measures, including usual activities and pain or discomfort. However, differences in cognitive test scores between the groups were not statistically significant. These results suggest that any potential benefits should be discussed specifically—not presented as evidence that the therapy addresses every long COVID symptom.
Safety was the trial’s primary focus. No serious adverse events were reported, although two treated participants experienced mild treatment-emergent adverse events. These findings are encouraging, but a 30-person study cannot reliably identify uncommon complications or establish long-term safety.
Why Cautious Optimism Matters
The key word is preliminary. This was a small, single-site, single-blind trial, and fatigue outcomes relied on participants’ reports. StemCyte funded the research and participated in its design, analysis, and report writing—important context when evaluating the findings.
Researchers propose that immune modulation and tissue-repair effects could help explain the results, but the trial did not establish the mechanism. Larger, independently replicated studies with longer follow-up are needed to determine who might benefit and how durable those benefits could be.
For readers following regenerative medicine, this study offers a useful example of promising research—not a proven cure.
